Vertex Pharmaceuticals Inc
VRTX455.450USD
-4.610-1.00%
Fechamento 06/13, 16:00（ET）Cotações atrasadas em 15 min
117.04BValor de mercado
PerdaP/L TTM
Mais detalhes de Vertex Pharmaceuticals Inc Empresa
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Informações da empresa
Código da empresaVRTX
Nome da EmpresaVertex Pharmaceuticals Inc
Data de listagemJul 24, 1991
Fundado em1989
CEODr. Reshma Kewalramani
Número de funcionários6100
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 24
Endereço50 Northern Avenue
CidadeBOSTON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02210
Telefone16173416393
Sitehttps://www.vrtx.com/
Código da empresaVRTX
Data de listagemJul 24, 1991
Fundado em1989
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
61.30K
+158.88%
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
7.12K
+12.60%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.83K
+8.93%
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.72K
+86.33%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
61.30K
+158.88%
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de abr
Moeda: USDAtualizado em: dom, 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
TRIKAFTA
10.24B
92.91%
Other CF products
781.50M
7.09%
Por RegiãoUSD
Nome
Receita
Proporção
United States
6.68B
60.66%
Europe
3.45B
31.34%
Other
881.30M
8.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
TRIKAFTA
10.24B
92.91%
Other CF products
781.50M
7.09%
Distribuição de ações
Atualizado em: qui, 15 de mai
Atualizado em: qui, 15 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Capital World Investors
11.11%
The Vanguard Group, Inc.
9.10%
Capital Research Global Investors
5.66%
BlackRock Institutional Trust Company, N.A.
5.45%
State Street Global Advisors (US)
4.59%
Other
64.08%
Investidores
Investidores
Proporção
Capital World Investors
11.11%
The Vanguard Group, Inc.
9.10%
Capital Research Global Investors
5.66%
BlackRock Institutional Trust Company, N.A.
5.45%
State Street Global Advisors (US)
4.59%
Other
64.08%
Tipos de investidores
Investidores
Proporção
Investment Advisor
50.54%
Investment Advisor/Hedge Fund
37.24%
Research Firm
2.55%
Pension Fund
2.43%
Bank and Trust
2.04%
Sovereign Wealth Fund
1.47%
Hedge Fund
1.30%
Insurance Company
0.17%
Individual Investor
0.15%
Other
2.11%
Participação acionária institucional
Atualizado em: dom, 19 de jan
Atualizado em: dom, 19 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
2908
248.19M
96.64%
-1.58M
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.89M
96.55%
-7.11M
2023Q1
2468
250.11M
97.13%
-4.74M
2022Q4
2454
248.59M
96.73%
-7.80M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Capital World Investors
28.33M
11.02%
+1.51M
+5.65%
Dec 31, 2024
The Vanguard Group, Inc.
23.15M
9%
+102.48K
+0.44%
Dec 31, 2024
Capital Research Global Investors
10.43M
4.06%
+1.43M
+15.85%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
14.33M
5.57%
-90.57K
-0.63%
Dec 31, 2024
State Street Global Advisors (US)
11.98M
4.66%
+163.16K
+1.38%
Dec 31, 2024
Fidelity Management & Research Company LLC
9.11M
3.54%
-1.25M
-12.07%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.65M
2.2%
-287.65K
-4.85%
Dec 31, 2024
Wellington Management Company, LLP
5.92M
2.3%
+1.12M
+23.28%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
5.33M
2.07%
+71.48K
+1.36%
Feb 28, 2025
JP Morgan Asset Management
4.62M
1.8%
-403.93K
-8.04%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sex, 6 de jun
Atualizado em: sex, 6 de jun
Nome
Proporção
Tema Neuroscience and Mental Health ETF
11.55%
VanEck Biotech ETF
10.4%
Invesco Nasdaq Biotechnology ETF
7.69%
ProShares Ultra Nasdaq Biotechnology
7.31%
iShares Biotechnology ETF
6.77%
Natixis Loomis Sayles Focused Growth ETF
5.02%
Franklin Genomic Advancements ETF
4.69%
Indexperts Gorilla Aggressive Growth ETF
4.1%
JPMorgan Healthcare Leaders ETF
3.97%
PGIM Jennison Better Future ETF
3.61%
Ver Mais
Tema Neuroscience and Mental Health ETF
Proporção11.55%
VanEck Biotech ETF
Proporção10.4%
Invesco Nasdaq Biotechnology ETF
Proporção7.69%
ProShares Ultra Nasdaq Biotechnology
Proporção7.31%
iShares Biotechnology ETF
Proporção6.77%
Natixis Loomis Sayles Focused Growth ETF
Proporção5.02%
Franklin Genomic Advancements ETF
Proporção4.69%
Indexperts Gorilla Aggressive Growth ETF
Proporção4.1%
JPMorgan Healthcare Leaders ETF
Proporção3.97%
PGIM Jennison Better Future ETF
Proporção3.61%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
